Entering text into the input field will update the search result below

EMA grants Prime status for Roche's risdiplam for SMA

Dec. 17, 2018 7:53 AM ETRoche Holding AG (RHHBY) StockBIIB, NVS, RHHBY, IONS, CYTK, PTCT, SRRKBy: Douglas W. House, SA News Editor
  • The European Medicines Agency grants PRIME status for Roche's (OTCQX:RHHBY) risdiplam for the treatment of spinal muscular atrophy (SMA).
  • PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive guidance on development and accelerated review of the market application.
  • The company is developing the orally administered survival motor neuron-2 gene splicing modifier with the SMA Foundation and PTC Therapeutics (NASDAQ:PTCT).
  • SMA-related tickers: (NASDAQ:BIIB)(NASDAQ:IONS)(NASDAQ:SRRK)(NYSE:NVS)(NASDAQ:CYTK)

Recommended For You

More Trending News

About RHHBY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RHHBY--
Roche Holding AG